NYSE: COR

Cencora (COR) Stock Analysis & Forecast

Nov 16 close

$356.94−2.09 (−0.6%)

Gekko Brief

Nov 16 close

Cencora closed at $356.94 on 16 November 2026, -0.6% on the day. The price sits above both the 50-day ($327.68) and 200-day ($316.70) moving averages, inside a 52-week range of $244.82 to $377.54. The GekkoIndex reads 49.6, in the Neutral zone, down 3.3 points over five sessions. Gekko Fair Value is $545.35, so the price is 34.5% below it.

The next earnings report is due on 3 February 2027, 78 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 4.9% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Seasonally, the next 20 trading days from this point averaged 0% over the last 5 years, rising in 2 of them.

9 firms rate the stock: 7 buy, 2 hold and 0 sell, with a consensus target of $381.25. A typical daily move is about 2.9%, and a typical 20-day move about 4.7%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 16, 2026 close.

Cencora price vs fair value

▲$543.28$356.94Nov ’25May ’26Nov ’26
Close $356.94200-day averageGekko Fair Value $543.28

Cencora quick facts

Market cap
$68.11B
P/E ratio
20
Forward P/E
18.3
EPS, TTM
$17.95
Revenue, TTM
$337.4B
Profit margin
1%
Dividend yield
0.69%
Beta
0.57
Volume
1.03M avg 1.38M
1-year return
−2.3%
Typical daily move
±2.9%
Typical 20-day move
±4.7%
50-day average
$327.68
200-day average
$316.70
Next earnings
Feb 3 before open
Shares outstanding
190.8M
52-week range
$244.82$377.54

Cencora swing-trade checklist

Cencora scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $356.94 is above the 50-day ($327.68) and 200-day ($316.70) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    49.6, Neutral

    Reading 49.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    34.3% below

    Price is 34.3% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: Congress 1 buy / 0 sales.

    See smart money
  • Earnings risksupportive

    Reports in 78 days

    Next report Feb 3, 2027, 78 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −0.7% on average

    From this point in the calendar, the next 20 trading days averaged −0.7% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Cencora stock chart and price history

Cencora closed at $356.94 on Nov 16, 2026, −2.3% over the past year, inside a 52-week range of $244.82 to $377.54.

Close50-day average200-day averageVolume
Cencora share price, past year, with 50-day and 200-day moving averages and volume$250$275$300$325$375DecJan 2026FebMarAprMayJunJulAugSepOctNov356.94

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+4.7%
3 months
+12.9%
6 months
+36.3%
1 year
−2.3%
The full COR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open COR in Gekko

Follow Cencora through every session

Put COR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track COR in GekkoFree for 7 days. No credit card required.

About Cencora

Cencora sources and distributes pharmaceutical products across the United States and international markets. Through its U.S. Healthcare Solutions segment, it supplies generic and injectable medications, over-the-counter health items, and home healthcare equipment, along with specialized products such as plasma, blood derivatives, and vaccines. The company is also known for its work in animal health, offering pharmaceuticals, vaccines, parasiticides, diagnostics, and feed ingredients for companion and production animals.

Cencora's customers include acute care hospitals, health systems, retail and mail-order pharmacies, medical clinics, oncologists, dialysis clinics, and other healthcare providers. Beyond product supply, it provides pharmacy management, staffing, and consulting services, builds supply management software, handles packaging for institutional and retail healthcare settings, and supports clinical trials, post-market approval, and commercialization for biotechnology and pharmaceutical manufacturers, including data analytics and outcomes research. Its International Healthcare Solutions division handles global pharmaceutical wholesale operations, commercialization support, and logistics for the biopharmaceutical sector, reaching pharmacies, doctors, health centers, and hospitals abroad.

The company traces back to 1871 and was previously named AmerisourceBergen Corporation before taking the name Cencora in August 2023. It is headquartered in Conshohocken, Pennsylvania, and its shares are listed on the NYSE under the ticker COR.

Listed
NYSE
Sector
Distribution services
Industry
Medical distributors
Website
cencora.com

Cencora GekkoIndex: the smart money zone

Cencora’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.6, in the Neutral zone, down 3.3 points over five sessions.

010049.6Neutral

Down 3.3 points over five sessions.

Reading for Nov 16, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying27−0.5%+1.1%+4.6%+4.1%
Accumulation181+0.6%+1.2%+2.5%+4.7%
Neutral (current zone)433+0.5%+0.6%+0.9%+2.7%
Distribution64−0.6%+0.4%+0.3%+1.3%
Selling2Too few readings yet

Average COR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the COR price, zone by zone.Track COR in Gekko

Is Cencora stock overvalued? Gekko Fair Value

Cencora trades 34.3% below Gekko Fair Value of $543.28, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Cencora shares are worth, recalculated every trading day.

$543.28

Gekko Fair Value, Nov 17, 2026

34.3% Undervalued

At the end of Aug 2026 the price was 31.7% below the estimate.

Gekko Fair ValueShare price, month end
$543$357Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open COR in Gekko

Cencora insider and Congress trading

No open-market insider purchases were filed for Cencora, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for COR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every COR insider filing, plotted on the chart in Gekko.Open COR in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 4

From congressional disclosures, which report amounts as ranges.

Buybacks

Cencora has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$33K
As a share of market cap
0.00%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold COR.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Cencora earnings: next date and track record

Cencora reports on Feb 3, 2027, before the open (78 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±4.9%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−2.2%Feb ’25−2.4%May ’25−4.8%Aug ’25+4.6%Nov ’25−2.7%Feb ’26−16.4%May ’26+6.1%Aug ’26−0.2%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
Cencora reported fiscal 2026 full-year adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. The company completed the OneOncology acquisition in February and announced acquisitions of iSouth Retina and a majority interest in American Oncology Network, expanding its MSO platform. Cencora also divested all non-core businesses within its 'Other' segment to concentrate capital on its pharmaceutical-centric specialty strategy.
Guidance
Management enters fiscal 2027 with stated momentum, noting outlook is aligned with long-term targets when excluding divested businesses. No specific revenue or EPS targets were provided in this excerpt, but confidence in long-term growth trajectory was emphasized.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$4.66
est $4.58
+1.7%$88.35B
est $87.95B
+0.5%−0.2%
Aug 5, 2026$4.48
est $4.37
+2.5%$84.75B
est $84.31B
+0.5%+6.1%
May 6, 2026$4.75
est $4.73
+0.4%$78.36B
est $81.09B
−3.4%−16.4%
Feb 4, 2026$4.08
est $4.05
+0.7%$85.93B
est $86.06B
−0.1%−2.7%
Nov 5, 2025$3.84
est $3.79
+1.3%$83.73B
est $83.46B
+0.3%+4.6%
Aug 6, 2025$4.00
est $3.85
+3.9%$80.66B
est $80.09B
+0.7%−4.8%
May 7, 2025$4.42
est $4.11
+7.5%$75.45B
est $75.68B
−0.3%−2.4%
Feb 5, 2025$3.73
est $3.52
+6.0%$81.49B
est $78.31B
+4.1%−2.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Cencora stock forecast and analyst price targets

Analysts’ average 12-month price target for Cencora is $382.42, +7.1% from the last close, from 9 firms rating the stock in the last 90 days.

$382.42consensus 12-month target, +7.1% from the last close
Low $330High $413
Buy7
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 9 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Bank of America SecuritiesHold, maintained$360+0.9%
Nov 10J.P. MorganBuy, maintained$413+15.7%
Nov 5RBC CapitalHold, reiterated$330−7.5%
Nov 5Robert W. BairdBuy, maintained$405+13.5%
Nov 5Bank of America SecuritiesHold, maintained$360+0.9%
+0.9%average 20-day move after past Neutral readings
−0.7%average move over the next 20 trading days in the last 5 years
±2.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Cencora seasonality: the next 20 trading days

Over the next 20 trading days from Nov 17, Cencora averaged −0.7% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−0.6%2021+5.0%2022+2.6%2023−6.3%2024−6.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+2.4%4 of 5
Next 10 trading days+1.4%3 of 5
Next 15 trading days−0.4%3 of 5
Next 20 trading days−0.7%2 of 5
Next 30 trading days+0.8%3 of 5

For scale, COR’s typical 20-trading-day move in either direction is about 4.7%.

Cencora market cap and key statistics

Cencora’s market cap is $68.11B, with a P/E ratio of 20 and revenue of $337.4B over the last twelve months.

Valuation

Market cap
$68.11B
P/E ratio
20
Forward P/E
18.3
EPS, TTM
$17.95
Gekko Fair Value
$543.28

Trading

Volume
1.03M
Avg volume, 20 days
1.38M
52-week high
$377.54
52-week low
$244.82
Shares outstanding
190.8M

Financials

Revenue, TTM
$337.4B
Profit margin
1%
Return on equity
129%
Quarterly earnings growth, YoY
+11.9%

Risk and income

Beta
0.57
Typical daily move
±2.9%
Typical 20-day move
±4.7%
Dividend yield
0.69%

Cencora peers

Cencora’s 3 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
MCKMcKesson−1.2%Distribution2.6% above
CAHCardinal Health0.0%Distribution31.0% below
HSICHenry Schein−0.9%Neutral5.3% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Distribution services

Cencora stock FAQ

What is Cencora’s market cap?

Cencora’s market cap is $68.11B at the Nov 16, 2026 close of $356.94, with 190.8M shares outstanding. The shares trade on a P/E ratio of 20.

What is the Cencora stock forecast?

The consensus analyst 12-month price target for Cencora is $382.42, +7.1% from the last close. Of the 9 firms that rated the stock in the last 90 days, 7 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Cencora stock overvalued or undervalued?

On Gekko’s estimate Cencora is undervalued: the Nov 16, 2026 close of $356.94 is 34.3% below Gekko Fair Value of $543.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Cencora report earnings next?

Cencora is expected to report on Feb 3, 2027, before the market opens (78 days away). Analysts expect earnings of $4.53 per share on revenue of $90.46B. Cencora beat the earnings estimate in 8 of its last 8 reports, moving 4.9% on average across the report.

What is Cencora’s 52-week high and low?

Cencora’s 52-week high is $377.54 and its 52-week low is $244.82; it closed at $356.94 on Nov 16, 2026, −2.3% over the past year.

Is Cencora stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, smart money and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Cencora the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,476 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.